# Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

> **NCT00800605** · PHASE3 · COMPLETED · sponsor: **Alachua Government Services, Inc.** · enrollment: 7250 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Vero cell-derived, trivalent, seasonal influenza vaccine
- **BIOLOGICAL:** Placebo: Phosphate-buffered saline

## Key facts

- **NCT ID:** NCT00800605
- **Lead sponsor:** Alachua Government Services, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-05
- **Final completion:** 2009-06
- **Target enrollment:** 7250 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800605, "Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00800605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*